

Mansur Shomali, MD

### Journal Articles

Engagement and Outcomes Associated with Contextual Annotation Features of a Digital Health Solution. Dugas M, Wang W, Crowley K, Iyer AK, Peeples M, Shomali M, Gao GG. J Diabetes Sci Technol. 2022 Jul;16(4):804-811.

Diabetes Technology in Primary Care: The Future Is Here, Almost. Shomali ME. Clin Diabetes. 2020 Dec;38(5):417-420.

Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials. Shomali ME, Ørsted DD, Cannon AJ. Diabet Med. 2017 Feb;34(2):197-203.

Liraglutide and Renal Outcomes in Type 2 Diabetes. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. N Engl J Med. 2017 Aug 31;377(9):839-848.

Insulin and Its Cardiovascular Effects: What Is the Current Evidence? Dongerkery SP, Schroeder PR, Shomali ME. Curr Diab Rep. 2017 Oct 23;17(12):120.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. N Engl J Med. 2013 Oct 3;369(14):1327-35.

Diabetes treatment in 2025: can scientific advances keep pace with prevalence? Shomali M. Ther Adv Endocrinol Metab. 2012 Oct;3(5):163-73.

Incidence of extreme hyperglycemia and hypoglycemia in hospitalized patients during the month of July in teaching hospitals. Shomali M, Cheikh M. J Community Hosp Intern Med Perspect. 2012 Jul 16;2(2). Print 2012.

Add-on therapies to metformin for type 2 diabetes. Shomali M. Expert Opin Pharmacother. 2011 Jan;12(1):47-62.

Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study. Shomali ME, Herr DL, Hill PC, Pehlivanova M, Sharretts JM, Magee MF. Diabetes Technol Ther. 2011 Feb;13(2):121-6.

Hypoglycemia in the hospital. Shomali M. J Community Hosp Intern Med Perspect. 2011 Jul 18;1(2). Print 2011.

Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes. Quianzon CL and Shomali ME. U.S. Endocrinology 2011;7(2):102–7.

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Diabet Med. 2010 Sep;27(9):1024-32.PMID: 20722676

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Campbell RK, Cobble ME, Reid TS, Shomali ME. J Fam Pract. 2010 Sep;59(9 Suppl 1):S5-9.

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2

diabetes. Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. *Diabetes Obes Metab*. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. PMID:20590735

Practical applications of therapy with a glucagon-like peptide-1 receptor agonist. Shomali ME. *J Fam Pract*. 2009 Sep;58(9 Suppl Treating):S35-43.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode, for the LEAD-3 (Mono) Study Group *Lancet* 2009 Feb 7;373(9662):473-81.

Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L. *Diabetes Care* 2009 March 16.

Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. Donekal S, Shomali ME. *Diabetes Res Clin Pract*. 2008 May;80(2):e4-6. Epub 2008 Mar 7.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone; a randomized, double-blind, non-inferiority trial. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group. *Diabetes Obes Metab* 2007 Mar 9(2); 194-205.

Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Shomali ME, Katznelson L. *Pituitary*. 2002;5(2):89-98.

Juxtamembrane region of the amino terminus of the corticotrophin releasing factor receptor type 1 is important for ligand interaction. Assil IQ, Qi LJ, Arai M, Shomali ME, Abou-Samra AB. *Biochemistry* 2001; 40: 1187-95.

An oxidation resistant radioligand for corticotropin-releasing factor receptors. Assil IQ, Shomali ME, Abou-Samra AB. *Peptides*. 2001 Jul;22(7):1055-61.

Cushing's syndrome: from patients to proteins. Shomali ME, Hussain MA. *Eur J Endocrinol*. 2000 Sep;143(3):313-5.

Hypercalcemia in a woman with hypoparathyroidism associated with increased parathyroid hormone-related protein during lactation. Shomali ME, Ross DS. *Endocr Pract*. 1999 Jul-Aug;5(4):198-200.

Medical therapy for gonadotroph and thyrotroph tumors. Shomali ME, Katznelson L. *Endocrinol Metab Clin North Am*. 1999 Mar;28(1):223-40, viii.

The use of anti-aging hormones. Melatonin, growth hormone, testosterone, and dehydroepiandrosterone: consumer enthusiasm for unproven therapies. Shomali ME. *Md Med J*. 1997 Apr;46(4):181-6.

### Books

Graham K and Shomali ME. *Diabetes Essentials*. Robert Rose, Toronto 2020.

Graham K and Shomali ME. *Diabetes Cookbook: Meals for Good Health*. Robert Rose, Toronto 2020.

Graham K and Shomali ME. *The Complete Guide to Type 2 Diabetes*. Robert Rose, Toronto 2020.

Shomali ME., ed. Section IX: Endocrine Disease. In Israel JL and Tunkel AR, Eds. *Medicine: A Competency-Based Companion*. Saunders Elsevier; Philadelphia. 2013

Shomali ME. Perspective: Medical therapy of tumors of the pituitary and sellar region. In *Principles and Practice of Stereotactic Radiosurgery*. Lawrence Chin and William Regine, eds. Springer, New York, 2008